Report Content
Chapter 1 Methodology & Scope
1.1 Methodology
1.2 Market scope & definitions
1.3 Base estimates and calculations
1.3.1 North America
1.3.2 Europe
1.3.3 Asia Pacific
1.3.4 Latin America
1.3.5 MEA
1.4 Forecast calculations
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Leuprolide acetate industry 3600 synopsis, 2018 - 2032
2.1.1 Business trends
2.1.2 Application trends
2.1.3 Product form trends
2.1.4 Route of administration trends
2.1.5 Distribution channel trendss
2.1.6 Regional trends
Chapter 3 Leuprolide Acetate Industry Insights
3.1 Industry landscape, 2018-2032
3.2 Industry ecosystem analysis
3.2.1 Vendor matrix
3.2.2 Distribution channel analysis
3.3 Pricing analysis, 2018 - 2032
3.3.1 Pricing analysis, by region
3.3.2 Pricing analysis, by country
3.4 Cost structure analysis
3.5 Industry impact forces
3.5.1 Growth drivers
3.5.1.1 Rising incidence of cancer worldwide
3.5.1.2 Increasing drug related research and development activities
3.5.1.3 Growing number of women population base suffering from endometriosis
3.5.1.4 Upsurge in awareness regarding precocious puberty
3.5.2 Industry pitfalls & challenges
3.5.2.1 High costs associated with leuprolide acetate drugs
3.5.2.2 Adverse price control policies
3.6 Growth potential analysis
3.6.1 By application
3.6.2 By product form
3.6.3 By route of administration
3.6.4 By distribution channel
3.7 COVID- 19 impact analysis
3.8 Regulatory landscape
3.8.1 U.S.
3.8.2 Europe
3.8.3 Asia pacific
3.9 Porter's analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape
4.1 Introduction
4.1.1 AbbVie
4.1.2 Ferring B.V.
4.1.3 Merck & Co., Inc.
4.2 Competitive dashboard, 2021
4.3 Company market share, 2021
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic outlook matrix
Chapter 5 Leuprolide Acetate Market, By Application
5.1 Key application trends
5.2 Cancer
5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.2 Prostate cancer
5.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.3 Breast cancer
5.2.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.4 Cervix uteri
5.2.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.5 Ovary cancer
5.2.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.6 Testis
5.2.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.2.7 Others
5.2.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.3 Radical prostatectomy
5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.4 Central precocious puberty
5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.5 Endometriosis
5.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.6 Hormone therapy
5.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.7 Uterine fibroids
5.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
5.8 Others
5.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 6 Leuprolide Acetate Market, By Product Form
6.1 Key product form trends
6.2 Lyophilized powder
6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.3 Pre-filled syringes
6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
6.4 Vials
6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 7 Leuprolide Acetate Market, By Route of Administration
7.1 Key route of administration trends
7.2 Intradermal
7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.3 Intramuscular
7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
7.4 Subcutaneous
7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 8 Leuprolide Acetate Market, By Distribution Channel
8.1 Key distribution channel trends
8.2 Hospital pharmacy
8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.3 Retail pharmacy
8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
8.4 Online pharmacy
8.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
Chapter 9 Leuprolide Acetate Market, By Region
9.1 Key regional trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Russia
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Thailand
9.4.7 Vietnam
9.4.8 Philippines
9.4.9 CIS
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Guatemala
9.5.5 Colombia
9.5.6 Costa Rica
9.5.7 Chile
9.5.8 Peru
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Iraq
9.6.5 Yemen
9.6.6 Lebanon
9.6.7 Syria
Chapter 10 Company Profiles
10.1 Dr. Reddy’s Laboratories Ltd
10.2 Varian Pharmed
10.3 Ferring Pharmaceuticals Pvt Ltd
10.4 Teva Pharmaceutical Industries Ltd.
10.5 Sun Pharmaceutical Industries Ltd.
10.6 BACHEM
10.7 Merck KGaA
10.8 Takeda Pharmaceutical Company Limited.
10.9 Taj Pharmaceuticals
10.10 AbbVie Inc.
10.11 Anhui Anke Bioengineering (Group) Co., Ltd.
10.12 Verity Pharmaceuticals
10.13 Tolmar Pharmaceuticals Inc.
10.14 Intas Pharmaceuticals Ltd.
10.15 Beijing Biote Pharmaceutical Co., Ltd.
10.16 Cipla Inc.
10.17 Livzon
10.18 Amneal Pharmaceuticals Inc.
10.19 Midas Pharma GmBH
10.20 Actiza Pharmaceutical Private Limited
10.21 Bharat Serums and Vaccines Limited (BSV)
10.22 Jagsonpal Pharmaceuticals Ltd.
10.23 Zydus Group.
10.24 Eugia
10.25 Sayre Therapeutics.
